Who We Are ? Endonovo Therapeutics (OTCQB: ENDV) is a

New Post Public Reply Private Reply Replies (0) Message Board
CyberC
688
Who We Are ?
Endonovo Therapeutics (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical™ Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders.



Endonovo's Electroceutical™ Therapy is FDA-Cleared for the palliative treatment of pain and post-surgical edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Endonovo's Electroceutical™ Therapy has CMS National Coverage for the treatment of chronic wounds. The Company's current pipeline of clinical-stage Electroceutical™ Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis.



Our Vision
Endonovo means to renew from within. Our vision is to develop safe, wearable non-invasive medical devices to deliver our Electroceutical™ Therapy, which harnesses bioelectricity to restore key electrochemical processes that initiate the anti-inflammatory and growth factor cascades necessary for healing to occur.

Endonovo Therapeutics, Inc. (ENDV) Stock Research Links

ENDV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Gaby Natale to Inspire at Procter & Gamble's LatinOvation

Updated Category News Views 189

Gaby Natale to Motivate at Procter & Gamble's LatinOvation Gaby Natale, a celebrated triple Emmy award-winning journalist and bestselling author, is poised to deliver the impactful closing keynote at Procter & Gamble's annual LatinOvation event. This year, the gathering continues to honor the substantial contributions from the Hispanic community, rallying around the theme...

Continue Reading
GitLab's Market Resilience and Adjustments in Earnings Outlook

Updated Category News Views 124

GitLab's Steady Growth Amid Price Forecast Adjustments In recent developments, analyst Pinjalim Bora from JP Morgan has reiterated a Neutral rating on GitLab Inc. (NASDAQ: GTLB), adjusting the price forecast from $65 down to $62. Quarterly Performance Shines GitLab’s recent quarterly earnings report revealed surprising strength, with the company posting earnings of 33...

Continue Reading
Understanding Recent Trading Trends for Exxon Mobil Options

Updated Category News Views 73

Insights into Exxon Mobil Options Trading Recent analysis highlights a bullish trend in Exxon Mobil's trading activity. Our examination of the stock, identified by the symbol XOM, has uncovered significant patterns in the options market. Our investigation into the history of options trading shows that 53% of traders are leaning towards a bullish outlook, while 33% have a...

Continue Reading
Ming Tsai Launches Exciting New Frozen Meals Across Stores

Updated Category News Views 519

Ming Tsai Launches Exciting New Frozen Meals Nationwide Ming Tsai, an acclaimed chef known for his innovative culinary skills, has recently introduced a new line of products called Mings™ frozen meals. This line aims to transport your taste buds across Asia with authentic flavors that can now be found in Walmart stores across the country. A Culinary Adventure Awaits...

Continue Reading
Truist Financial Corporation Insights on Q3 2024 Performance

Updated Category News Views 237

Truist Financial Corporation Reports Strong Q3 2024 Results Truist Financial Corporation (NYSE: TFC) released its results for the third quarter of 2024 today, showcasing its fiscal health and commitment to enhancing customer experience. The company continues to focus on delivering robust financial performance while engaging its client base and broader community. Key...

Continue Reading